BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 14627671)

  • 41. Absence of the Birt-Hogg-Dubé gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility.
    Preston RS; Philp A; Claessens T; Gijezen L; Dydensborg AB; Dunlop EA; Harper KT; Brinkhuizen T; Menko FH; Davies DM; Land SC; Pause A; Baar K; van Steensel MA; Tee AR
    Oncogene; 2011 Mar; 30(10):1159-73. PubMed ID: 21057536
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genome-Wide Uniparental Disomy and Copy Number Variations in Renal Cell Carcinomas Associated with Birt-Hogg-Dubé Syndrome.
    Iribe Y; Yao M; Tanaka R; Kuroda N; Nagashima Y; Nakatani Y; Furuya M
    Am J Pathol; 2016 Feb; 186(2):337-46. PubMed ID: 26776076
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hereditary kidney cancer: unique opportunity for disease-based therapy.
    Linehan WM; Pinto PA; Bratslavsky G; Pfaffenroth E; Merino M; Vocke CD; Toro JR; Bottaro D; Neckers L; Schmidt LS; Srinivasan R
    Cancer; 2009 May; 115(10 Suppl):2252-61. PubMed ID: 19402075
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Novel FLCN Variant in a Suspected Birt-Hogg-Dubè Syndrome Patient.
    Bandini E; Zampiga V; Cangini I; Ravegnani M; Arcangeli V; Rossi T; Mammi I; Schiavi F; Zovato S; Falcini F; Calistri D; Danesi R
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569793
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The genetic basis of cancer of the kidney.
    Linehan WM; Walther MM; Zbar B
    J Urol; 2003 Dec; 170(6 Pt 1):2163-72. PubMed ID: 14634372
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic basis of cancer of the kidney: disease-specific approaches to therapy.
    Linehan WM; Vasselli J; Srinivasan R; Walther MM; Merino M; Choyke P; Vocke C; Schmidt L; Isaacs JS; Glenn G; Toro J; Zbar B; Bottaro D; Neckers L
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6282S-9S. PubMed ID: 15448018
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hereditary Renal Cancer Syndromes.
    Yanus GA; Kuligina ES; Imyanitov EN
    Med Sci (Basel); 2024 Feb; 12(1):. PubMed ID: 38390862
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.
    Chen J; Futami K; Petillo D; Peng J; Wang P; Knol J; Li Y; Khoo SK; Huang D; Qian CN; Zhao P; Dykema K; Zhang R; Cao B; Yang XJ; Furge K; Williams BO; Teh BT
    PLoS One; 2008; 3(10):e3581. PubMed ID: 18974783
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of 1733insC mutations in an Asian family with Birt-Hogg-Dubé syndrome.
    Kawasaki H; Sawamura D; Nakazawa H; Hattori N; Goto M; Sato-Matsumura KC; Akiyama M; Shimizu H
    Br J Dermatol; 2005 Jan; 152(1):142-5. PubMed ID: 15656814
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Birt-Hogg-Dubé (BHD) syndrome: report of two novel germline mutations in the folliculin (FLCN) gene.
    Palmirotta R; Donati P; Savonarola A; Cota C; Ferroni P; Guadagni F
    Eur J Dermatol; 2008; 18(4):382-6. PubMed ID: 18573707
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Kidney cancer: Links between hereditary syndromes and sporadic tumorigenesis.
    Alchoueiry M; Cornejo K; Henske EP
    Semin Diagn Pathol; 2024 Jan; 41(1):1-7. PubMed ID: 38008653
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative analyses define differences between BHD-associated renal tumour and sporadic chromophobe renal cell carcinoma.
    Jikuya R; Johnson TA; Maejima K; An J; Ju YS; Lee H; Ha K; Song W; Kim Y; Okawa Y; Sasagawa S; Kanazashi Y; Fujita M; Imoto S; Mitome T; Ohtake S; Noguchi G; Kawaura S; Iribe Y; Aomori K; Tatenuma T; Komeya M; Ito H; Ito Y; Muraoka K; Furuya M; Kato I; Fujii S; Hamanoue H; Tamura T; Baba M; Suda T; Kodama T; Makiyama K; Yao M; Shuch BM; Ricketts CJ; Schmidt LS; Linehan WM; Nakagawa H; Hasumi H
    EBioMedicine; 2023 Jun; 92():104596. PubMed ID: 37182269
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Birt-Hogg-Dubé syndrome with clear-cell and oncocytic renal tumour and trichoblastoma associated with a novel FLCN mutation.
    Imada K; Dainichi T; Yokomizo A; Tsunoda T; Song YH; Nagasaki A; Sawamura D; Nishie W; Shimizu H; Fukagawa S; Urabe K; Furue M; Hashimoto T; Naito S
    Br J Dermatol; 2009 Jun; 160(6):1350-3. PubMed ID: 19416240
    [No Abstract]   [Full Text] [Related]  

  • 54. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
    Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
    Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel familial germline mutation in the initiator codon of the BHD gene in a patient with Birt-Hogg-Dubé syndrome.
    Bessis D; Giraud S; Richard S
    Br J Dermatol; 2006 Nov; 155(5):1067-9. PubMed ID: 17034545
    [No Abstract]   [Full Text] [Related]  

  • 56. Establishment and characterization of renal carcinoma cell lines from a Bhd gene mutant (Nihon) rat.
    Matsumoto I; Kouchi M; Okimoto K; Kijima K; Ueda T; Hirayama Y; Inoue T; Seki T; Hino O
    Tumour Biol; 2009; 30(5-6):249-56. PubMed ID: 19816092
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple/bilateral renal tumors in patients with Birt-Hogg-Dubé syndrome.
    Fahmy W; Safwat AS; Bissada NK; Curry N; Guirguis N; Clarke HS; Fraig M; Finkbeiner A
    Int Urol Nephrol; 2007; 39(4):995-9. PubMed ID: 17211573
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The impact of germline BHD mutation on histological concordance and clinical treatment of patients with bilateral renal masses and known unilateral oncocytoma.
    Boris RS; Benhammou J; Merino M; Pinto PA; Linehan WM; Bratslavsky G
    J Urol; 2011 Jun; 185(6):2050-5. PubMed ID: 21496834
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Colon adenocarcinoma and Birt-Hogg-Dubé syndrome in a young patient: case report and exploration of pathologic implications.
    Jirka GW; Lefler DS; Russo J; Bashir B
    Cancer Biol Ther; 2023 Dec; 24(1):2184153. PubMed ID: 36859772
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma.
    Kawakami T; Chano T; Minami K; Okabe H; Okada Y; Okamoto K
    Hum Mol Genet; 2006 Mar; 15(6):821-30. PubMed ID: 16439445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.